Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 12c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($0.86), $0.12 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $303.33 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ScanSource (SCSC) Tops Q4 EPS by 32c
• Citi cuts Weibo stock rating to Neutral, lowers price target